Skip to main content
. 2019 Jun 14;10(6):453. doi: 10.3390/genes10060453

Figure 3.

Figure 3

Schematic structure of Rp-cGMPS analogues. Arrows illustrate typical structural positions in Rp-cGMPS used for the introduction of substituents to generate Rp-cGMPS analogues with improved inhibitory potency for cGMP-dependent protein kinase I or II. (A) Position 1, N2: Addition of β-phenyl-1,N2-etheno-modifications (PET) with varying additional substituents (R1) to Rp-cGMPS [65,66]. (B) Position 8: Addition of halogens (e.g., bromine (Br)) or sulfur-connected aromatic ring systems with varying additional substituents (R2) [65,67].